Category Archives: Crohn’s disease

Funding the new biologics – CCOHTA report on the cost effectiveness of infliximab for Crohn’s disease: CONCLUSIONS

In summary, the CCOHTA cost-utility analysis is methodologically rigorous, and remains the only fully published economic model of the use of infliximab for refractory Crohn’s disease. When interpreting its results, decision makers are encouraged to consider the many assumptions required … Continue reading

Funding the new biologics – CCOHTA report on the cost effectiveness of infliximab for Crohn’s disease: Pearls and pitfalls Part 3

As with any cost utility Markov model, the CCOHTA analysis required three key data components to characterize each health state: estimated probabilities of ‘transitioning’ to other health states; profiles of resource utilization and costs accrued while in the state; and … Continue reading

Funding the new biologics – CCOHTA report on the cost effectiveness of infliximab for Crohn’s disease: Pearls and pitfalls Part 2

The model’s base-case analysis found usual care to be the least costly but least effective strategy. A single infusion of infliximab improved outcomes, but at an incremental cost of $181,201 for each additional QALY gained. The re-treatment and maintenance strategies … Continue reading

Funding the new biologics – CCOHTA report on the cost effectiveness of infliximab for Crohn’s disease: Pearls and pitfalls Part 1

Infliximab, a monoclonal antibody to tumour necrosis factor (TNF)-alpha, is approved in Canada for the treatment of Crohn’s disease that is either refractory to other medical treatments or complicated by enterocutaneous fistulas. Efficacy for each of these indications has been … Continue reading